Clinical Trial Update: Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC [NA]

View source ↗

Summary

A clinical trial evaluating donafenib as adjuvant therapy after microwave ablation for recurrent hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Microwave Ablation | NA | Status: RECRUITING